Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Innovate to Study Larazotide's Effect on Microbiome of Children with EED
Innovate to Study Larazotide's Effect on Microbiome of Children with EED
Innovate to Study Larazotide's Effect on Microbiome of Children with EED
Submitted by
admin
on July 31, 2018 - 7:13pm
Source:
CP Wire
News Tags:
Innovate Biopharmaceuticals
microbiome
celiac disease
larazotide
EED
Headline:
Innovate to Study Larazotide's Effect on Microbiome of Children with EED
snippet:
Larazotide has received Fast Track designation from the FDA for celiac disease.
Innovate is preparing to enter Ph III registration clinical trials for celiac disease later in 2018
Larazotide has demonstrated a favorable safety profile comparable to placebo for long-term chronic administration (over 800 patients)
Do Not Allow Advertisers to Use My Personal information
